To buy or not to buy Abbott Labs? In this video, Fool health care analyst Brenton Flynn gives three reasons why you should. First, health care spending is likely to grow both in the U.S. and in emerging markets. Second, Abbott's nutrition division offers not only baby formula that is increasingly popular in emerging markets, but also diet supplements for older adults, a growing market domestically. Lastly, Abbott should increase its earnings by streamlining its operations and improving business efficiency.
S&P 500
5,911.69
-0.0%
-$0.48
DJI
42,270.07
+0.1%
+$54.34
NASDAQ
19,113.77
-0.3%
-$62.11
Bitcoin
104,290.00
+0.4%
+431.18
AAPL
$201.47
+0.8%
+$1.52
AMZN
$205.07
-0.3%
-$0.63
GOOG
$173.06
+0.1%
+$0.10
META
$648.23
+0.5%
+$3.18
MSFT
$460.71
+0.4%
+$2.03
NVDA
$135.22
-2.9%
-$3.97
TSLA
$346.82
-3.2%
-$11.61
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.